Rockwell Medical (RMTI) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Talphera (TLPH) has outperformed Rockwell Medical (RMTI) over the past year, losing 18.2% versus a loss of 33.7%. Over five years, RMTI leads with a -87.8% price change compared with -94.7% for TLPH. Talphera is the larger company by market cap ($55.5 million vs $32.3 million), about 1.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RMTI | TLPH |
|---|---|---|
| Share price | $8.02 | $1.07 |
| Market cap | $32.32M | $55.54M |
| 1-day change | -2.43% | -0.92% |
| YTD return | -3.37% | -5.26% |
| 1-year return | -33.72% | -18.18% |
| 5-year return | -87.85% | -94.71% |
| Forward P/E | 114.57 | — |
| EPS (TTM) | $-1.34 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.90 | $1.57 |
| 52-week low | $4.89 | $0.69 |
| Distance from 52-week high | -37.83% | -31.85% |
| Analyst consensus | none | none |
| Avg. price target upside | +149.38% | +192.52% |
| Average volume | 26.44K | 238.38K |
| Shares outstanding | 4.03M | 51.91M |
| Employees | 157 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed RMTI by 15.5 percentage points over the past year.
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Health Care · Biotechnology: Pharmaceutical Preparations · 157 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
RMTI vs TLPH FAQ
Which is bigger, Rockwell Medical or Talphera?
Talphera (TLPH) is larger, with a market capitalization of $55.54M compared with $32.32M for Rockwell Medical (RMTI).
Which stock has performed better over the past year, RMTI or TLPH?
TLPH returned -18.18% over the past 12 months, compared with -33.72% for RMTI (price return, excluding dividends). Past performance does not predict future results.
Are Rockwell Medical and Talphera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.